Dr. Ismail-Beigi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Ave
Cleveland, OH 44106Phone+1 216-844-8500
Education & Training
- Johns Hopkins UniversityResidency, Internal Medicine, 1971 - 1972
- University of California (San Francisco)Residency, Internal Medicine, 1968 - 1971
- Johns Hopkins UniversityResidency, Internal Medicine, 1967 - 1968
- Johns Hopkins University School of MedicineInternship, Transitional Year, 1966 - 1967
- Johns Hopkins University School of MedicineClass of 1966
Certifications & Licensure
- OH State Medical License 1993 - 2026
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc ana...Samin Ghanbari, Sepehr Gohari, Tara Reshadmanesh, Mahsa Mahjani, Shahram Arsang-Jang
Journal of Diabetes and Metabolic Disorders. 2024-06-01 - 5 citationsInsulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis.Mohammad E Khamseh, Mojtaba Malek, Soodeh Jahangiri, Sohrab Nobarani, Azita Hekmatdoost
Digestive Diseases and Sciences. 2024-04-01 - Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.Mohsen Dehghani, Masoumeh Sadeghi, Farzaneh Barzkar, Zohreh Maghsoomi, Leila Janani
Frontiers in Endocrinology. 2024-01-01
Press Mentions
- Researchers Call for Paradigm Shift in Type 2 Diabetes TreatmentJune 20th, 2017
- ACCORD Analyses Find a Few Faint Glimmers of HopeJune 29th, 2010
Grant Support
- Novel PET Imaging Of Glucose TransportNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
- AccordNational Heart, Lung, And Blood Institute2010
- Carbohydrate Metabolic PathwaysNational Institute Of Diabetes And Digestive And Kidney Diseases2007
- Regulation Of GLUT 1 FunctionNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2006
- Thyroidal Regulation Of Cardiac Sodium/Potassium Atpase Expression And EnergeticsNational Heart, Lung, And Blood Institute2002–2005
- Regulation Of GLUT1 Gene Expression By HypoxiaNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2001
- Thyroid Hormone Control Of Cardiac Sodium/Potassium Atpase ExpressionNational Heart, Lung, And Blood Institute1996–2000
- Regulation Of GLUT1 Glucose Transporter ExpressionNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1996
- Physiological Regulation Of NA 1 K-AtpaseNational Institute Of General Medical Sciences1992
- Physiological Regulation Of NA, K-AtpaseNational Institute Of General Medical Sciences1988–1992
- Physiological Control Of Myocardial Na,K-Pump ExpressionNational Heart, Lung, And Blood Institute1988–1991
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: